ORTEXORTEX News
Tracking IFF? Get live short interest, options flow, and signals on ORTEX.Sign up free →
IF
Trader NoteIFF

IFF Shorts Retreat as Stock Outpaces Specialty Chemical Peers

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 21 Oct 2026, 18:31

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Among its closest specialty chemical peers, IFF carries one of the lighter short positions this week. Short interest in International Flavors & Fragrances has fallen to 5.5% of free float, while PPG and SHW both gained ground at a similar pace on the week. IFF's 3.4% weekly gain outpaced a peer median of roughly 1.7%, with PPG up 3.9% and Sherwin-Williams up 3.7% over the same period, suggesting broad specialty chemicals strength rather than an IFF-specific catalyst.

The short position has been unwinding steadily. Shares short have dropped 5.1% over the past week and are down nearly 11% over the past month, retreating from a local peak above 19.9 million shares in early September to 14.2 million today. The borrow market corroborates the easing pressure: availability is running at 356%, meaning there are more than three and a half shares available to lend for every one already borrowed. That is well above the 52-week tightest reading of 188%, which came in mid-September when shorts were at their most active. Cost to borrow has drifted lower too, sitting at 0.44%, down 9% on the week and close to the lowest level of the past six weeks.

Options positioning is broadly neutral. The put/call ratio is at 0.79, just under one standard deviation above its 20-day average of 0.77. That is far below the 52-week high of 1.40 and close to the midpoint of the year's range, leaving no obvious signal of either aggressive hedging or speculative call-buying ahead of the November 3 earnings date.

The Street leans constructive, though not uniformly. Barclays raised its target to $105 from $96 last Thursday while keeping an Overweight rating, the most recent significant move. Argus and Citigroup both hold Buy ratings at targets around $95 to $100. The mean analyst target across the group sits at $96.41, a 5.7% premium to the current price of $91.21, which frames consensus as modestly positive rather than strongly so. The PE multiple has expanded by roughly 1.4 points over the past month to 23.6x, and the price-to-book ratio has risen 0.15 points over the same period, both consistent with a stock that has re-rated upward. The ORTEX factor scores add some nuance: dividend quality ranks in the 76th percentile, and 30-day EPS momentum is in the 68th percentile, while the 90-day EPS momentum score of 12 and EPS surprise rank of 16 point to a more checkered recent estimate history.

The most distinctive element in the ownership picture is the scale of the director purchase made in June. Director Paul Fribourg bought 273,500 shares at roughly $74.28 in early June for a combined $20.3 million, a discretionary open-market purchase with no 10b5-1 plan attached. The stock has since risen to $91.21, a gain of around 23% from those levels. Dodge & Cox remains the largest institutional holder with a 14.5% stake, having added 534,000 shares in the most recent reported quarter. BlackRock and Invesco also added shares in the quarter to September, with Invesco's 1.46 million share increase the largest absolute addition among the top holders.

With Q3 results due on November 3, the level worth watching is whether short interest, currently unwinding gradually, accelerates further toward the lows last seen in early September, or whether it rebuilds as the print approaches.

Stocks in this article

See the live data behind this article on ORTEX.

Open IFF on ORTEX →

How this article was generated

Generated
21 Oct 2026, 18:35
Data as of
21 Oct 2026, 18:31
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.